[ORGANIZATION]
Retatrutide
Featured in 17 tracked stories · first seen
Situations
GLP-1 drugs: clinical trends, safety, and market shifts
343 clusters · 1318 sources · last updated
Latest: GLP-1 medications linked to weight regain and hair loss
The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, neurodegenerative, heart, sleep apnea, and addiction healt
Retatrutide development and regulatory actions
7 clusters · 36 sources · last updated
Latest: Eli Lilly experimental drug retatrutide shows promise for knee osteoarthritis
Retatrutide, an investigational synthetic peptide developed by Eli Lilly, is being studied for its metabolic potential in managing food regulation, sugar, and weight. As a triple receptor agonist, it mimics natural gut a
Eli Lilly EloraTZP and retatrutide obesity drug clinicals
4 clusters · 38 sources · last updated
Latest: Eli Lilly's retatrutide outperforms Ozempic in weight loss trial
Eli Lilly has reported results from Phase 2b clinical trials for EloraTZP, a combination therapy involving eloralinantide and tirzepatide designed to treat obesity and type 2 diabetes. Data indicates the combination tar
Also covered in
-
Eli Lilly expands manufacturing and oncology pipeline
[BUSINESS] · 3 sources ·
-
University of Pennsylvania researchers use AI to study unapproved Retatrutide use
[HEALTH] · 2 sources ·
-
Retatrutide shows clinical promise amid black market death reports
[HEALTH] · 3 sources ·
-
Boehringer Ingelheim reports Phase III success for obesity drug survodutida
[HEALTH] · 5 sources ·